Bausch Health Companies Inc. (NASDAQ:BHC) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55422	Articles
62513	Press releases

Headlines Articles Press releases Bausch Health Companies Inc.

Home
Companies
Bausch Health Companies Inc.

BRIEF

published on 07/11/2024 at 13:05, 4 months 10 days ago

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

Financial Results Conference Call Investor Relations Bausch Health 2024 Second Quarter
PRESS RELEASE

published on 07/11/2024 at 13:00, 4 months 10 days ago

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Bausch Health Companies Inc. to release Q2 2024 financial results on August 1, 2024. Conference call & webcast at 8:00 a.m. U.S. EST for results discussion & business update

Conference Call Bausch Health Companies Inc. Investor Relations Webcast Q2 2024 Financial Results
BRIEF

published on 06/20/2024 at 23:33, 5 months ago

Bausch Health Files Patent Infringement Lawsuit Against Norwich Pharmaceuticals

XIFAXAN Bausch Health Norwich Pharmaceuticals Patent Infringement IBS-D
PRESS RELEASE

published on 06/20/2024 at 23:28, 5 months ago

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Bausch Health and Salix Pharmaceuticals file patent infringement lawsuit against Norwich Pharmaceuticals over XIFAXAN. Company defends intellectual property rights

Salix Pharmaceuticals XIFAXAN Bausch Health Intellectual Property Patent Infringement
BRIEF

published on 06/20/2024 at 06:05, 5 months 1 day ago

Bausch Health Files Patent Infringement Lawsuit Against Norwich Pharmaceuticals

Bausch Health Norwich Pharmaceuticals Patent Infringement IBS-D XIFAXAN®
PRESS RELEASE

published on 06/20/2024 at 06:00, 5 months 1 day ago

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Bausch Health & Salix Pharmaceuticals file lawsuit against Norwich Pharmaceuticals for patent infringement on XIFAXAN. Company defends intellectual property vigorously

Salix Pharmaceuticals XIFAXAN Lawsuit Bausch Health Patent Infringement
BRIEF

published on 06/14/2024 at 20:35, 5 months 6 days ago

Bausch Health Reveals Promising Results in Clinical Trials of Amiselimod and Rifaximin

Ulcerative Colitis Bausch Health Amiselimod Rifaximin Hepatic Encephalopathy
PRESS RELEASE

published on 06/14/2024 at 20:30, 5 months 6 days ago

Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Bausch Health Companies Inc. presents positive data from Amiselimod clinical trials for ulcerative colitis treatment at global healthcare conferences. Rifaximin monotherapy data also showed promise for hepatic encephalopathy recurrence prevention

Bausch Health Companies Inc. Ulcerative Colitis Amiselimod Rifaximin Hepatic Encephalopathy
BRIEF

published on 05/23/2024 at 14:05, 5 months 29 days ago

Bausch Health Announces Expanded Public Drug Plan Listings for UCERIS® in Canada

Ulcerative Colitis Bausch Health Canada UCERIS Public Drug Plans
PRESS RELEASE

published on 05/23/2024 at 14:00, 5 months 29 days ago

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health Canada expands UCERIS availability in Canadian public drug plans for ulcerative colitis treatment. UCERIS foam offers better tolerability and application compared to enema

Ulcerative Colitis UCERIS Public Drug Plans Bausch Health Canada Gastrointestinal Franchise

Accesswire

Published on 11/21/2024 at 17:35, 1 hour 13 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 1 hour 18 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 2 hours 18 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 47 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 48 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 18:36, 12 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 50 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 57 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 57 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 2 hours 48 minutes ago

Director/PDMR Shareholding

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 50 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 23 hours 28 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 11 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE